Abstract Number: 36 • 2013 ACR/ARHP Annual Meeting
IFN-α Induces Altered Transitional B Cell Signaling and Function In Systemic Lupus Erythematosus
Background/Purpose: Previous experiments suggest that the B cells of lupus patients are hyper-responsive to B cell receptor engagement resulting in increased tyrosine phosphorylation and Ca2+mobilization. …Abstract Number: 37 • 2013 ACR/ARHP Annual Meeting
Follicular Entry Of Lymphotoxin-Expressing B Cells Via Type I Interferon Disrupts Marginal Zone Barrier Integrity and Exacerbates Systemic Autoimmunity
Background/Purpose: Marginal zone macrophages (MZMs), a small subset of specialized splenic macrophages located in the MZ, act as final follicular entry barrier to clear apoptotic…Abstract Number: 38 • 2013 ACR/ARHP Annual Meeting
Use Of An In Vitro Whole Blood Depletion ASSAY To Compare The Efficacy Of B CELL Depleting Agents In Patients With Systemic LUPUS Erythematosus
Background/Purpose: Variability in clinical response to B-cell depletion therapy (BCDT) with the anti-CD20mAb rituximab (RTX) has been well described in Systemic Lupus Erythematosus (SLE). Poor…Abstract Number: 11 • 2013 ACR/ARHP Annual Meeting
Catastrophic Antiphospholipid Syndrome (CAPS): Clinical, Immunologic Features, and Outcome Of 441 Patients From The “CAPS Registry”
Background/Purpose: To analyze the clinical and laboratory features as well as the precipitating factors, treatment and outcome of patients with catastrophic antiphospholipid syndrome (CAPS). Methods:…Abstract Number: L15 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety of CT-P13 (Infliximab Biosimilar) over Two Years in Patients with Ankylosing Spondylitis: Comparison Between Continuing with CT-P13 and Switching from Infliximab to CT-P13
Background/Purpose: CT-P13 is an infliximab (INX) biosimilar recently approved by the European Medicine Agency. PLANETAS was a 54-week (wk) randomized double-blind parallel group multicenter Phase…Abstract Number: L21 • 2013 ACR/ARHP Annual Meeting
Celastrol, a Triterpene from Tripterygium Wilfordii, Inhibits Neutrophil Extracellular Trap Formation
Background/Purpose: , Neutrophils provide the frontline of defense against invading pathogens. However, neutrophils also contribute to the development of autoimmune diseases. Recent studies suggest that…Abstract Number: 1 • 2013 ACR/ARHP Annual Meeting
Anti-â2GP1- Domain-1 Antibodies Are a Marker Of APS Severity
Background/Purpose: Autoantibodies targeting Domain-1(D1) of beta-2-glycoprotein-1(β2GP1) are common among patients with the antiphospholipid syndrome (APS)1. However, few studies assessed their clinical relevance and correlation with…Abstract Number: 2 • 2013 ACR/ARHP Annual Meeting
Charaterization Of Micrornas Involved In The Regulation Of Atherotrhombosis In Antiphospholipid Syndrome and Systemic Lupus Erythematosus
Background/Purpose: miRNAs are key players in pathophysiological processes, but no previous studies have investigated their asscociation with the cardiovascular and atherothrombotic risks observed in primary…Abstract Number: 3 • 2013 ACR/ARHP Annual Meeting
The Global Antiphospholipid Syndrome Score (GAPSS) In Primary APS
Background/Purpose: Antiphospholipid Syndrome (APS) is a heterogeneous entity with a wide variation in clinical course and laboratory profile. We aimed to evaluate the clinical utility…Abstract Number: 4 • 2013 ACR/ARHP Annual Meeting
Proteomic Analyses Of Monocyte Responses To IgG From Patients With Antiphospholipid Syndrome
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disorder characterised by recurrent vascular thrombosis (VT) and/or pregnancy morbidity (PM) caused by antiphospholipid antibodies (aPL). Whilst aPL are known…Abstract Number: 5 • 2013 ACR/ARHP Annual Meeting
Plasma Levels Of PF-4var/CXCL4L1, A Non Allelic Variant Of Platelet Factor-4 (PF-4/CXCL4), Are Elevated In Patients With Antiphospholipid Syndrome (APS)
Background/Purpose: Platelet derived chemokines, such as PF-4 and a recently isolated protein product of its nonallelic variant gene PF-4var, are implicated in several aspects of…Abstract Number: 6 • 2013 ACR/ARHP Annual Meeting
Researchers’ Own Experience In Managing Obstetric Complications In Pregnant Women With Antiphospholipid Syndrome
Background/Purpose: To analyse risk factors for obstetric pathology in patients with antiphospholipid syndrome (APS). To assess the effectiveness of treatment depending on pharmacotherapy. Methods:…Abstract Number: 7 • 2013 ACR/ARHP Annual Meeting
Prospective Validation Of The Global Antiphospholipid Syndrome Score (GAPSS)
Prospective Validation of the Global Antiphospholipid Syndrome Score (GAPSS) Background/Purpose: Backgrounds: This study was performed to prospectively and independently validate the GAPSS (1) (Global APS…Abstract Number: 8 • 2013 ACR/ARHP Annual Meeting
Clinical Evaluation Of Two Anti-Beta2glycoprotein I Domain 1 Autoantibody Assays To Aid In The Diagnosis and Risk Assessment Of The Antiphospholipid Syndrome
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by the presence of antibodies to phospholipids (aPL) and to β2glycoprotein I (β2GPI) in patients with thrombosis or pregnancy…Abstract Number: 9 • 2013 ACR/ARHP Annual Meeting
Domain 1 Is The Main Specificity Of Anti-β2glycoprotein I Antibodies In Systemic Autoimmune Diseases
Background/Purpose: Anti-β2glycoprotein I antibodies (a-β2GPI) are involved in the pathogenesis of the Antiphospholipid Syndrome (APS). Antibodies to the domain 1 of β2GP1 (a-β2GPI-D1) have been…